Cargando…
R&D Costs of New Medicines: A Landscape Analysis
Over the years, questions have been raised over R&D costs of new medicines. The aim of this study is to conduct a landscape review of the (drivers of) R&D costs of a new medicine derived from the peer-reviewed and grey literature. Included studies have drawn data either from confidential com...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576181/ https://www.ncbi.nlm.nih.gov/pubmed/34765624 http://dx.doi.org/10.3389/fmed.2021.760762 |
_version_ | 1784595831230300160 |
---|---|
author | Simoens, Steven Huys, Isabelle |
author_facet | Simoens, Steven Huys, Isabelle |
author_sort | Simoens, Steven |
collection | PubMed |
description | Over the years, questions have been raised over R&D costs of new medicines. The aim of this study is to conduct a landscape review of the (drivers of) R&D costs of a new medicine derived from the peer-reviewed and grey literature. Included studies have drawn data either from confidential company surveys or from publicly available company financial statements, in addition to accessing the literature and medicine information databases. Although there were differences in methodology, parameter values, samples and time periods between studies, estimates of R&D costs per new medicine (accounting for the cost of failures) ranged from US$944m to US$2,826m (adjusted to 2019 prices). The evidence also suggested that R&D costs per new medicine have increased over time. A few studies have broken down total costs and showed that clinical development accounts for 50-58% of R&D costs per new medicine. R&D costs were influenced by costs of discovery and pre-clinical development, costs of clinical development, cost of capital, company and product profile. Finally, cost estimates are likely to be dynamic as the biopharmaceutical industry and the broader environment continue to evolve. |
format | Online Article Text |
id | pubmed-8576181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85761812021-11-10 R&D Costs of New Medicines: A Landscape Analysis Simoens, Steven Huys, Isabelle Front Med (Lausanne) Medicine Over the years, questions have been raised over R&D costs of new medicines. The aim of this study is to conduct a landscape review of the (drivers of) R&D costs of a new medicine derived from the peer-reviewed and grey literature. Included studies have drawn data either from confidential company surveys or from publicly available company financial statements, in addition to accessing the literature and medicine information databases. Although there were differences in methodology, parameter values, samples and time periods between studies, estimates of R&D costs per new medicine (accounting for the cost of failures) ranged from US$944m to US$2,826m (adjusted to 2019 prices). The evidence also suggested that R&D costs per new medicine have increased over time. A few studies have broken down total costs and showed that clinical development accounts for 50-58% of R&D costs per new medicine. R&D costs were influenced by costs of discovery and pre-clinical development, costs of clinical development, cost of capital, company and product profile. Finally, cost estimates are likely to be dynamic as the biopharmaceutical industry and the broader environment continue to evolve. Frontiers Media S.A. 2021-10-26 /pmc/articles/PMC8576181/ /pubmed/34765624 http://dx.doi.org/10.3389/fmed.2021.760762 Text en Copyright © 2021 Simoens and Huys. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Simoens, Steven Huys, Isabelle R&D Costs of New Medicines: A Landscape Analysis |
title | R&D Costs of New Medicines: A Landscape Analysis |
title_full | R&D Costs of New Medicines: A Landscape Analysis |
title_fullStr | R&D Costs of New Medicines: A Landscape Analysis |
title_full_unstemmed | R&D Costs of New Medicines: A Landscape Analysis |
title_short | R&D Costs of New Medicines: A Landscape Analysis |
title_sort | r&d costs of new medicines: a landscape analysis |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576181/ https://www.ncbi.nlm.nih.gov/pubmed/34765624 http://dx.doi.org/10.3389/fmed.2021.760762 |
work_keys_str_mv | AT simoenssteven rdcostsofnewmedicinesalandscapeanalysis AT huysisabelle rdcostsofnewmedicinesalandscapeanalysis |